State of New Jersey Common Pension Fund D Purchases 11,181 Shares of Vaxcyte, Inc. $PCVX

State of New Jersey Common Pension Fund D increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 20.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,658 shares of the company’s stock after purchasing an additional 11,181 shares during the period. State of New Jersey Common Pension Fund D owned 0.05% of Vaxcyte worth $2,401,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Edgestream Partners L.P. purchased a new position in Vaxcyte in the second quarter worth approximately $1,610,000. Federated Hermes Inc. increased its position in shares of Vaxcyte by 6,856.3% in the 3rd quarter. Federated Hermes Inc. now owns 18,156 shares of the company’s stock valued at $654,000 after purchasing an additional 17,895 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Vaxcyte in the 3rd quarter valued at approximately $2,640,000. Quadrature Capital Ltd acquired a new stake in shares of Vaxcyte in the 2nd quarter valued at $1,359,000. Finally, Eventide Asset Management LLC lifted its position in shares of Vaxcyte by 80.4% during the 2nd quarter. Eventide Asset Management LLC now owns 848,141 shares of the company’s stock worth $27,573,000 after purchasing an additional 377,911 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, SVP Elvia Cowan sold 11,623 shares of the company’s stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total value of $556,974.16. Following the sale, the senior vice president owned 14,534 shares of the company’s stock, valued at approximately $696,469.28. This represents a 44.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Harpreet S. Dhaliwal sold 9,743 shares of Vaxcyte stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total transaction of $454,900.67. Following the sale, the insider owned 23,928 shares of the company’s stock, valued at approximately $1,117,198.32. This trade represents a 28.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.10% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on PCVX. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. Needham & Company LLC raised their price objective on shares of Vaxcyte from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Leerink Partners set a $77.00 price objective on shares of Vaxcyte and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Guggenheim reaffirmed a “buy” rating and issued a $116.00 target price on shares of Vaxcyte in a research report on Monday, February 2nd. Finally, BTIG Research reiterated a “buy” rating and set a $85.00 price target on shares of Vaxcyte in a research note on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $93.83.

Vaxcyte Stock Up 2.1%

Shares of NASDAQ:PCVX opened at $58.51 on Friday. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $84.01. The firm’s 50-day simple moving average is $50.05 and its 200-day simple moving average is $42.94. The company has a market cap of $7.66 billion, a price-to-earnings ratio of -12.09 and a beta of 1.33.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.